Table 1 Baseline characteristics of enrolled patients
Total n = 117 | Number or median value |
|---|---|
Age, median (range) | 44 (19–70) |
Gender, male | 70 (59.8%) |
Laboratory findings at diagnosis | |
Leukocyte count (×109/L) | 2.68 (0.4–112.0) |
Leukocytes count at peak (×109/L) | 16.6 (0.4–112.0) |
Hemoglobin (g/dL) | 8.9 (4.0–15.0) |
Platelet (×109/L) | 33.0 (5.0–163.0) |
Lactate dehydrogenase (LDH, U/L) | 692 (250–4070) |
Prothrombin time (PT, %) | 63.0 (35.0–101.0%) |
Partial thromboplastin time (aPTT, s) | 28.0 (20–45) |
Fibrinogen (mg/dL) | 134.0 (31.0–500.0) |
Antithrombin III (%) | 94.0 (49.0–150.0) |
D-dimer (mg/L) | 17.0 (1.0–36.0) |
Sanz criteria | |
High | 64 (54.7%) |
Intermediate | 19 (16.2%) |
Low | 34 (29.1%) |
Karyotype | |
Normal karyotype | 5 (4.3%) |
t(15;17) alone | 79 (67.5%) |
t(15;17) with 1 additional karyotype | 20 (17.1%) |
t(15;17) with ≥2 additional karyotype | 13 (11.1%) |
PML-RARa subtype | |
BCR1 | 85 (72.6%) |
BCR3 | 32 (27.4%) |
FLT3 mutation | |
No FLT3 mutation | 86 (73.5%) |
FLT3-ITD | 25 (21.4%) |
FLT3-TKD | 6 (5.1%) |
WT1 (copies/104 ABL), median (range) | |
At diagnosis (n = 117) | 18330 (20.0–236160.0) |
Post-induction (n = 117) | 63.9 (4.9–2360.0) |
Post 1st consolidation (n = 117) | 66.2 (1.1–2320.0) |
Post 2nd consolidation (n = 117) | 80.1 (1.3–2110.0) |
Post 3rd consolidation (n = 117) | 71.9 (10.8–808.0) |
aPost-maintenance 3 months (n = 117) | 70.0 (6.0–5520.0) |
aPost-maintenance 1 year (n = 87) | 57.5 (10.0–1630.0) |
aPost-maintenance 2 year (n = 62) | 54.4 (10.0–500.0) |
At relapse (n = 16) | 239.5 (77.1–34910.0) |
Leukapheresis at initial treatment | 20 (17.1%) |
Differentiation syndrome | 21 (17.9%) |
Hematological complete response | |
After induction | 115 (98.3%) |
After 2nd induction | 2 (1.7%) |
Complete molecular response (CMR) | |
After induction | 68 (58.1%) |
After 2nd induction | 2 (1.7%) |
After 1st consolidation | 42 (35.9%) |
After 2nd consolidation | 5 (4.3%) |